Assessment Of Quality-Of-Life Improvement In Severe Haemophilia-A With Inhibitor Patients Receiving Emicizumab Prophylaxis – Hospital Based Prospective Observational Study - Original Research Article

Authors

  • Dr. P Anil Kiran, Dr. A Vijaya Jyothi, Dr. BK Niranjan, Dr. Y Vamseedhar, Dr. K Lakshmi Sai Pooja

DOI:

https://doi.org/10.70082/9n07nr44

Abstract

To assess Quality of Life Improvement following Emicizumab prophylaxis in severe

Haemophilia- A patients

To evaluate the impact on ABR and functional independence in hemophilia A patients. To assess the quality-of-life improvement in severe hemophilia patients on Emicizumab prophylaxis for the period of 6 months

Downloads

Published

2025-08-16

Issue

Vol. 21 No. S8 (2025)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to Cite

Assessment Of Quality-Of-Life Improvement In Severe Haemophilia-A With Inhibitor Patients Receiving Emicizumab Prophylaxis – Hospital Based Prospective Observational Study - Original Research Article. (2025). The Review of Diabetic Studies , 579-583. https://doi.org/10.70082/9n07nr44